Overview

Charting the Future: Navigating the Evolving Healthcare Landscape and Trends in Asia Drug development and healthcare innovation in Asia is being rapidly reshaped by advancements in digital technologies, e.g. Artificial Intelligence.
(AI), cloud platforms, changing regulatory guidelines, and innovative clinical trial methodologies. These transformations are accelerating drug development, streamlining regulatory review processes, and enhancing patient engagement. To harness the full potential of these emerging opportunities and foster a dynamic and robust regulatory and clinical trial ecosystem, close collaborations among regulators, academia, patients, and industry are necessary.
The DIA Singapore Annual Meeting 2025 invites all stakeholders to share and review the evolving healthcare landscape challenges faced and lessons learned, and to identify future trends in the clinical research and regulatory environment in Asia. In-depth discussions will focus on key topics such as:
Join us at DIA Singapore 2025 to navigate these transformative changes and shape the future of healthcare in Asia.
Program Committee
-
Finny Liu, MSc, RPh APAC Regional Regulatory Policy Lead
Roche, Singapore -
Helene Sou, MSc, RAC Global Regulatory Policy and Innovation
Takeda Pharmaceutical Company Limited., Singapore -
Sandy Chan Associate Director, Regulatory Policy & Intelligence Lead- Asia Pacific
Johnson & Johnson, Singapore -
Martin Lim, MBA, MS Co-Founder and CEO
ONWARD Health Research, Singapore -
Thean Soo Lo
Regulatory Affairs Management Consultant, Singapore -
Edana Loke Assoc Dir - Asia, Australia, Africa, Middle East, Area & Affiliate Strategy
AbbVie Pte Ltd, Singapore -
Karin Markgraf Head Regulatory Affairs, APAC
Merck Pte Ltd, Singapore -
Audrey Ooi, MSc Head- Business Development
Clinical Research Malaysia, Malaysia
Have an account?